Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Jonnyboy85on Dec 10, 2020 9:44pm
170 Views
Post# 32085857

RE:Great News Recap

RE:Great News RecapThis one as well
RelevantStock wrote: That was a great CC, forget what the bashers say, here's a recap of the facts.  It was all great news, nothing was negative:

- Aristotle to be launched in Q1 2021, with the current covid clients (so probably Mercer included) and with healthcare partners (Tripp mentionned cancer clinics)

- Revenue trajectory remains the same for current Q4 - so it's still rising.  Covid revenues should continue to flow in probably untill 2022 according to the company projections

- The company has doubled in size in staffing, the lab will double in space during 2021

- Covid testing is going well, Barbados only has 2700 travelers going in and out of the country every week.  We are testing for Barbados, Hawaii, Arizona and China, and our good reputation brings us in conversation with other governments too.

- A quick mention of Stagezero's fair valuation was made.  Competitors were sold at 8 billions (Grail) and 2.15 billions (Thrive).

- Stagezero is dozen of years ahead the competition in their cancer testing technology according to the company

Those are the facts, whatever bashers say they are not stating facts or they are distorting the reality.  Good luck to all!



<< Previous
Bullboard Posts
Next >>